Supinoxin provides encouraging tumor inhibition data
March 2016


ROCKVILLE, Md.—The American Society for Clinical Oncology (ASCO) 2016 Genitourinary Cancers Symposium saw Rexahn Pharmaceuticals Inc. present new preclinical efficacy data for Supinoxin (RX-5902), its novel anticancer drug candidate. The compound is an orally administered, potential first- in-class, small-molecule inhibitor of phosphorylated-p68 (P-p68), which increases the activity of multiple cancer-related genes and plays a role in tumor progression and metastasis. Over-expression of P-p68 has been seen in solid tumors in melanoma, colon, ovarian and lung cancers. One study suggested Supinoxin achieved tumor growth inhibition of more than 60 percent in a xenograft model of renal cell cancer. Another xenograft study suggested it achieved dose-dependent tumor growth inhibition of more than 60 percent and a partial clinical response in 60 percent of the animals and a complete response in 10 percent of the animals at a dose of 70 mg/kg.

1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.